The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

The dermatology market remains highly competitive, with developers ranging from Big Pharma to biotechnology and specialty pharmaceutical firms. In recent years levels of innovation in the area have dwindled, allowing generic competition to erode the market share of several leading brands across major drug classes. As leading players continue to lose ground to smaller, specialised players, opportunities are being created for companies that can implement effective lifecycle management and identify lucrative niches.

‘The Dermatology Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage across key dermatology markets, with analysis of major currently marketed and pipeline drugs. The growth drivers and competitive dynamics of the area are assessed, with revenue and epidemiological forecasts provided for the period 2008-13. This report assesses the 10 leading companies in the dermatology market, examining their product portfolios and R&D pipelines to provide forecasts of their future competitive positions. This report also assesses prevalence rates across the seven major markets in addition to highlighting key trends across the global dermatology area, with coverage of over 95% of the total market.

Discover the key trends and growth drivers of the market for dermatology treatments, assess the competitive dynamics of leading companies and evaluate the future prospects of major products...

Some key findings from this report
• Increased safety concerns will restrict future growth for topical immunosuppressants such as Novartis’ Elidel and Astellas’ Protopic. Both these products have a declining market presence due to the FDA’s black box label warning in 2005 for potential cancer risk.

• Major branded oral acne treatments including Roaccutane will face growing generic competition over the 2008-2013 period. Leading brands in the topical acne treatment market are only expected to achieve marginal growth, while the total market for acne treatments is expected to amass $3b of revenue in 2013.

• The market for psoriasis treatments is forecast to register strong growth between 2008-2013, driven by the performances of key drugs such as Raptiva, Taclonex, Soriatane.

• The corticosteroid market is estimated to value $3.7b by 2013. Reformulated combination corticosteroid/anti-infective brands will continue be integral to the treatment of psoriasis and dermatitis and will continue to be the primary growth drivers within the area.

• Leo Pharma is believed to feature the strongest R&D pipeline in the dermatology market, with five projects currently in the mid to late stages of development. However, most leading companies have sparsely populated pipelines.

Top reasons to order your copy today
• Assess the epidemiology and forecast prevalence of major dermatological disorders including acne, psoriasis, dermatitis, rosacea across key geographies including the UK, Japan, France, Germany, Italy, Spain and the US.

• Evaluate the performances and strategies of major dermatology developers by examining the sales focus by drug class, currently marketed products and R&D portfolios of Bayer Schering, Galderma, GSK, Leo Pharma, Novartis, J&J, Roche, Sanofi-Aventis, Schering-Plough and Stiefel Labs.

• Examine the market dynamics for the global dermatology area and assess key trends and growth drivers across major treatment classes including corticosteroids, topical anti-infectives, acne and psoriasis.

• Forecast revenues for major currently marketed and pipeline dermatology products over 2008-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios.

• Identify the strategies that offer the greatest potential for success in the future, measure the impact of recent key events in the dermatology area and understand the latest issues affecting R&D.

Key issues examined in this report
• Generics threaten branded oral acne treatments. The majority of anti-acne brands, excluding Roaccutane and Diane, are based on generic molecules and formulations. This is expected to cause a shift in developmental focus to topical acne treatments and lead to a collapse in the value of the branded oral acne market.

• The future of corticosteroids. Triple combination products and reformulations are continuing to revive the sales of corticosteroid brands following poor performance in 2006. However, widespread genericization is threatening to stifle future growth in this class.

• Competition intensifies for psoriasis treatments. New molecular entities are largely focused upon psoriasis indications. The market is likely to witness strong growth in the forecast period as anti-TNF therapies such as Enbrel and Humira maintain strong performances.

• Shift in competitive landscape. With large pharma companies apparently neglecting their dermatology pipelines, small specialist players can build a market presence through strong lifecycle management strategies and targeted drug development.

Your questions answered
• What will be the major growth indications and drivers in the dermatology area between 2008-13?

• How will the competitive landscapes for acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infection treatments change by 2013?

• Which companies will become the key players in the dermatology market over the period 2008-2013?

• How have recent launches from companies such as GSK, Galderma and Leo Pharma/Warner Chilcott performed?

• Which pipeline products will be the growth drivers of the future?

• How significant is the threat of generics to the global market?

• What key trends and developments will influence the global dermatology market over 2008-13?

Report Highlights

[Fade out the market survey infos]

The Dermatology Market Outlook to 2013
Executive Summary 12
Overview and epidemiology of dermatological disorders 12
Global market analysis 12
Pipeline analysis 13
Competitive landscape 14
Chapter 1 Scope and methodology 16
Scope 16
Methodology 17
Chapter 2 Overview and epidemiology of dermatological disorders 20
Summary 20
Introduction 21
Acne 23
Overview 23
Epidemiology 25
Forecast epidemiology 25
Psoriasis 27
Overview 27
Epidemiology 28
Forecast epidemiology 29
Dermatitis 31
Overview 31
Epidemiology 33
Forecast epidemiology 34
Rosacea 36
Overview 36
Epidemiology 37
Forecast epidemiology 38
Infectious diseases of the skin 40
Overview 40
Viral infections of the skin 40
Bacterial infections of the skin 42
Fungal infections of the skin 43
Epidemiology 44
Viral infections of the skin 44
Bacterial infections of the skin 45
Fungal infections of the skin 46
Forecast epidemiology 47
Viral infections of the skin 47
Bacterial infections of the skin 48
Fungal infections of the skin 49
Chapter 3 Global market analysis 52
Summary 52
Introduction 53
Market analysis by country 53
Licensing trends 55
Market analysis by drug class 56
Leading brands dynamics 58
Dermatology sales forecast to 2013 60
Key events in the dermatology market 61
Biologics expected to drive growth in the psoriasis market 61
FDA requires class labeling and strengthened warnings for all four leading
anti-TNF therapies 61
Topical acne market moving towards combination products 61
Black box warning for Elidel and Protopic to adversely impact growth 62
Roche’s Roaccutane plagued by side-effect concerns and limited risk
management programs 62
Acne treatments 63
Market analysis by drug class 63
Leading acne treatment brands by drug class 64
Key brands analysis 65
Differine 65
Roaccutane 65
Acne treatment sales forecast to 2013 67
Psoriasis treatments 68
Market analysis by drug class 68
Leading psoriasis treatment brands by drug class 69
Key brands analysis 70
Raptiva 70
Soriatane 71
Psoriasis treatment sales forecast to 2013 72
Corticosteroid treatments 73
Market analysis by drug class 73
Leading corticosteroid treatment brands by drug class 74
Key brands analysis 75
Olux 75
Corticosteroid treatment sales forecast to 2013 76
Anti-infective treatments 77
Market analysis by drug class 77
Leading anti-infective treatment brands by drug class 78
Key brands analysis 79
Lamisil 79
Bactroban 80
Aldara 80
Zovirax 81
Anti-infective treatments sales forecast to 2013 83
Non steroidal products 84
Market analysis by drug class 84
Non steroidal brands by drug class 85
Key brands analysis 85
Elidel 85
Protopic 87
Non steroidal treatments sales forecast to 2013 88
Chapter 4 Pipeline analysis 90
Summary 90
Introduction 91
Key trends in R&D 91
Celgene’s apremilast may be an alternative to current anti-TNF therapies 93
Intense competition in psoriasis, but voclosporin could compete on better
side-effect profile and cost 93
Collagenex (Galderma) licenses becocalcidol from QuatRx 93
Reformulation products gaining traction 94
Dermatology pipeline 95
Leading drugs in development 97
Profiles of key pipeline products 98
Recently marketed drugs 98
Altabax 98
Desonate (desonide hydrogel) 99
Humira 101
Ziana 103
Oracea 105
Taclonex 107
Drugs in registration 108
Ustekinumab (CNTO–1275) 108
Panaclar/BG-12 110
Drugs in Phase III clinical studies 112
Voclosporin (ISA-237) 112
ABT-874 (formerly J-695) 113
Drugs in Phase II clinical studies 114
Apremilast (CC-10004) 114
COL-118 116
Pipeline forecast 118
Chapter 5 Competitive landscape 122
Summary 122
Introduction 123
Sales performance of leading players 123
Detailed analysis of leading dermatology players 130
Stiefel Labs 130
Overview 130
Sales focus by drug class 130
Marketed product portfolio 131
R&D pipeline analysis 132
Strategic and growth analysis 132
Johnson & Johnson (J&J) 133
Overview 133
Sales focus by drug class 133
R&D pipeline analysis 135
Sanofi-Aventis 136
Overview 136
Sales focus by drug class 136
Marketed product portfolio 137
R&D pipeline analysis 138
Strategic and growth analysis 138
Novartis 138
Overview 138
Sales focus by drug class 139
Marketed product portfolio 140
R&D pipeline analysis 141
Strategic and growth analysis 142
GlaxoSmithKline (GSK) 142
Overview 142
Sales focus by drug class 143
Marketed product portfolio 144
R&D pipeline analysis 145
Strategic and growth analysis 145
Galderma 146
Overview 146
Sales focus by drug class 146
Marketed product portfolio 148
R&D pipeline analysis 149
Strategic and growth analysis 149
Leo Pharma 149
Overview 149
Sales focus by drug class 150
Marketed product portfolio 151
R&D pipeline analysis 152
Strategic and growth analysis 153
Bayer-Schering Pharma 154
Overview 154
Sales focus by drug class 154
Marketed product portfolio 155
R&D pipeline analysis 156
Strategic and growth analysis 156
Schering-Plough 157
Overview 157
Sales focus by drug class 157
Marketed product portfolio 158
R&D pipeline analysis 159
Strategic and growth analysis 159
Roche 160
Overview 160
Sales focus by drug class 160
Marketed product portfolio 161
R&D pipeline analysis 161
Strategic and growth analysis 162
Chapter 6 Appendix 164
IMS data 164
D1A1 – Topical dermatological anti-fungals 164
D1A2 – Systemic dermatological anti-fungals 164
D1A3 – Topical scalp anti-fungals 164
D5A0 – Topical anti-psoriasis products 164
D5B0 – Systemic anti-psoriasis products 164
D5X0 – Other non-steroidal products for inflammatory skin disorders 164
D6A0 – Topical antibiotics and/or sulphonamides 164
D6D1 – Topical anti-virals 164
D6D9 – Other topical products used in viral infections 164
D7A0 – Plain topical corticosteroids 164
D7B1 – Combinations of corticosteroids with anti-bacterials 164
D7B2 – Combinations of corticosteroids with anti-fungals 164
D7B3 – Combinations of corticosteroids with anti-bacterials 164
D7B4 – Other corticosteroid combinations 164
D10A0 – Topical anti-acne preparations 164
D10B0 – Oral anti-acne preparations 164
Glossary 165
Biologics 166
Monoclonal antibody 166
Anti-TNF therapies 166
Atopic dermatitis 166
Rosacea 166
Psoriasis 166
Pleuromutilin 167
Psoriasis Area and Severity Index (PASI) 167
Clinical Erythema Assessment (CEA) 167
Index 168
[Fade out table of contents]

Table 2.1: Estimated prevalence of dermatological conditions across the seven major markets, 2007 21
Table 2.2: Estimated prevalence of acne across the seven major markets, 2007 25
Table 2.3: Forecast epidemiology of acne across the seven major markets, 2007–13 26
Table 2.4: Estimated prevalence of psoriasis across the seven major markets, 2007 28
Table 2.5: Forecast epidemiology of psoriasis across the seven major markets, 2007–13 30
Table 2.6: Estimated prevalence of dermatitis across the seven major markets, 2007 34
Table 2.7: Forecast epidemiology of dermatitis across the seven major markets, 2007–13 35
Table 2.8: Estimated prevalence of rosacea across the seven major markets, 2007 38
Table 2.9: Forecast epidemiology of rosacea across the seven major markets, 2007–13 39
Table 2.10: Estimated prevalence of viral infections of the skin across the seven major markets, 2007 44
Table 2.11: Estimated prevalence of bacterial infections of the skin across the seven major markets, 2007 45
Table 2.12: Estimated prevalence of fungal infections of the skin across the seven major markets, 2007 46
Table 2.13: Forecast epidemiology of viral infections of the skin across the seven major markets, 2007–13 47
Table 2.14: Forecast epidemiology of bacterial infections of the skin across the seven major markets, 2007 48
Table 2.15: Forecast epidemiology of fungal infections of the skin across the seven major markets, 2007–13 49
Table 3.16: The global dermatology market by drug class 2006–07 56
Table 3.17: Leading brands in the global dermatology market, 2006–07 58
Table 3.18: Dermatology market sales forecast by drug class 2007–13 60
Table 3.19: The global acne market by drug class, 2006–07 63
Table 3.20: Leading acne treatments in the global dermatology market, 64
Table 3.21: Anti-acne products sales forecast, 2007–13 67
Table 3.22: The global psoriasis market by drug class, 2006–07 68
Table 3.23: Leading psoriasis treatments in the global dermatology market, 2006–07 69
Table 3.24: Anti-psoriasis sales forecast, 2007–13 72
Table 3.25: The global corticosteroid market by drug class, 2006–07 73
Table 3.26: Leading corticosteroid treatments in the global dermatology market, 2006–07 74
Table 3.27: Corticosteroid treatments sales forecast, 2007–13 76
Table 3.28: The global anti-infectives market by drug class, 2006–07 77
Table 3.29: Leading anti-infective treatments in the global dermatology market, 2006–07 78
Table 3.30: Anti-infective treatments sales forecast, 2007–13 83
Table 3.31: Non steroidal treatments by drug class, 2006–07 84
Table 3.32: Non steroidal treatments in the global dermatology market, 85
Table 3.33: Other leading dermatology treatments sales forecast, 2007–13 88
Table 4.34: Dermatology pipeline by indication and stage of development, 1H2008 95
Table 4.35: An overview of Altabax 98
Table 4.36: An overview of Desonate 99
Table 4.37: Humira REVEAL data 102
Table 4.38: Humira versus placebo 102
Table 4.39: Humira versus placebo 103
Table 4.40: An overview of Ziana 103
Table 4.41: An overview of Oracea 105
Table 4.42: An overview of Taclonex 107
Table 4.43: An overview of Ustekinumab 108
Table 4.44: An overview of Panaclar 110
Table 4.45: An overview of Voclosporin (ISA-237) 112
Table 4.46: An overview of ABT-874 113
Table 4.47: An overview of Apremilast 114
Table 4.48: An overview of COL-118 116
Table 4.49: Dermatology disorders pipeline forecast, 2008–13 ($m) 118
Table 5.50: Leading Players in the global dermatology market, 2007–13 ($m) 124
Table 5.51: Stiefel Labs' leading dermatology product portfolio, 2006–07 131
Table 5.52: J&J’s leading dermatology product portfolio, 2006–07 134
Table 5.53: Sanofi-Aventis’ leading dermatology product portfolio, 2006–07 137
Table 5.54: Novartis’ leading dermatology product portfolio, 2006–07 140
Table 5.55: Novartis’ dermatology R&D product pipeline, 2007 141
Table 5.56: GSK’s leading dermatology product portfolio, 2006–07 144
Table 5.57: GSK’s dermatology R&D product pipeline, 2007 145
Table 5.58: Galderma’s leading dermatology product portfolio, 2006–07 148
Table 5.59: Leo Pharma’s leading dermatology product portfolio, 2006–07 151
Table 5.60: Leo Pharma’s dermatology R&D product pipeline, 2007 152
Table 5.61: Bayer Schering’s leading dermatology product portfolio, 2006–07 155
Table 5.62: Schering Plough’s leading dermatology product portfolio, 2006–07 158
Table 5.63: Roche’s leading dermatology product portfolio, 2006–07 161
Figure 2.1: Mechanism of acne formation 23
Figure 2.2: Disease progression and symptoms of acne 24
Figure 2.3: Common forms of psoriasis 27
Figure 2.4: Types of dermatitis 32
Figure 2.5: Types of contact dermatitis 33
Figure 2.6: Subtypes of rosacea 37
Figure 2.7: Types of viral infections 41
Figure 2.8: Types of bacterial infections 42
Figure 2.9: Types of fungal infections 43
Figure 3.10: Global dermatology market share by geography, 2007, US$m 53
Figure 3.11: Sales of types of dermatology brands, 2006–07 55
Figure 4.12: Prevailing R&D approaches, 2008 92
Figure 4.13: Leading recently launched products and late-stage R&D in the dermatology market, 2008 97
Figure 5.14: Market share of key players by sales value, 2007 126
Figure 5.15: Projected market share of key players by sales value, 2013 127
Figure 5.16: Market share and ranking of leading players in the global dermatology market, 2007– 13 128
Figure 5.17: Stiefel Labs’ dermatology sales by drug class, 2007 130
Figure 5.18: J&J’s dermatology sales by drug class, 2007 133
Figure 5.19: Sanofi-Aventis’ dermatology sales by drug class, 2007 136
Figure 5.20: Novartis’ dermatology sales by drug class, 2007 139
Figure 5.21: GSK’s dermatology sales by drug class, 2007 143
Figure 5.22: Galderma’s dermatology sales by drug class, 2007 147
Figure 5.23: Leo Pharma’s dermatology sales by drug class, 2007 150
Figure 5.24: Bayer-Schering’s dermatology sales by drug class, 2007 154
Figure 5.25: Schering Plough’s dermatology sales by drug class, 2007 157
Figure 5.26: Roche’s dermatology sales by drug class, 2007 160
[Fade out list of tables / figures]